Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024

10 Minutes of Antitrust: Tech Legislation, Litigation, and Risk Mitigation

Where Things Stand on Drug Pricing at the Halfway Point of 2023

Five Drug Pricing Issues to Watch in 2023

2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes

Is It Game Over for PlayStation Store Antitrust Suit?

Federal Legislators and FTC Keep PBMs Center Stage in Drug Pricing Debate

Drug Pricing Issues to Watch in 2022

United States: Pharmaceutical Antitrust 2022

States Remain the Drivers of New Drug Pricing Legislation As Washington Weighs In

House Republicans Introduce Bill to Renew 2015 Trade Promotion Authority Law and Establish New Negotiating Objectives for Pharmaceuticals

Third Circuit: Pharmaceutical Cases

Technology Industry Should Watch Closely as the Executive Branch and Lawmakers Set Their Sights on Antitrust

Analysis: FTC Encouraged to Ban or Limit Non-Compete Agreements in July 9, 2021 Executive Order; Breaks With Tradition, And Follows Trend of Heightened Antitrust Focus on Labor Markets

What Does President Biden’s July 9, 2021 Executive Order on Competition Mean for the Pharma Industry?

Sweeping US Order on “Promoting Competition”

What’s next for drug pricing in the US?

Federal Lawmakers Turn Their Sights to Drug Pricing, Introducing a Package of Bills Seeking Changes to Antitrust and Patent Law

US antitrust spotlight on the technology industry

President Biden Signs Legislation Boosting Generic and Biosimilar Drugs